Suraksha Diagnostic Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.

Ebitda Margin CompressionResults View source PDF Explain this filing

SURAKSHA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.2%Reaction day

₹299.25

prior close

₹299.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%-1.4% vs market

Healthcare Service Provider peers, median of 20sector+0.7%-1.9% vs sector

On the reaction day the stock moved 1.4 pts less than Nifty Microcap 250 and 1.9 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.9

10m

-1.3

15m

-2.3

30m

-3.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.2+0.2-1.4+0.7-1.9

Next day

-0.7+0.2-0.9+0.1-0.8

+0.3+0.9-0.6-1.4+1.6

+0.9+0.1+0.8-0.8+1.7

+4.9+1.6+3.3-2.0+6.9

+6.6+2.8+3.8-1.2+7.8

+5.4+3.0+2.4-3.0+8.5

15d

+1.4+2.8-1.4-0.6+2.0

+3.6+3.1+0.5-0.7+4.3

-4.4+1.4-5.9-3.7-0.8

+4.3+1.4+2.9-5.3+9.6

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 20Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Suraksha Diagnostic Limited submitted its unaudited financial results for the quarter ended June 30, 2025, approved by the Board on August 8, 2025. On a standalone basis, revenue from operations rose about 16% YoY to ₹7,027.90 lakhs from ₹6,043.29 lakhs, while profit after tax grew around 18% YoY to ₹984.87 lakhs (from ₹833.05 lakhs). Standalone EPS stood at ₹1.89 versus ₹1.56 a year earlier. On a consolidated basis, including the newly acquired subsidiary Fetomat Wellness, revenue was ₹7,258.63 lakhs and PAT was ₹917.51 lakhs. The statutory auditor, MSKA & Associates, issued an unmodified limited review conclusion on both sets of results.

Likely market impact

A steady quarter showing healthy double-digit growth in both revenue and profits, supported by the recent Fetomat acquisition now contributing to consolidated numbers. However, standalone EBITDA margin dipped slightly YoY (roughly 35% to 34%), which investors should watch for cost pressure, even as headline numbers remain positive.